+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Adult-onset Still's Disease - Epidemiology Forecast to 2030

  • ID: 5206755
  • Report
  • December 2020
  • Region: Global
  • 65 pages
  • DelveInsight
This ‘Adult-onset Still's Disease - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Adult-onset Still's Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Adult-onset Still's Disease: Understanding

The Adult-onset Still's Disease (AOSD) epidemiology report gives a thorough understanding of AOSD by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for AOSD in the US and Europe. Moreover, the report covers the AOSD scenario's detailed information in seven major countries (US, EU5, and Japan).

Epidemiology Perspective

This section encompassing adult-onset Still's disease epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The AOSD epidemiology data are studied through all possible divisions to understand the disease scenario in 7MM better. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation

The AOSD epidemiology covered in the report provides historical and forecasted AOSD epidemiology scenarios in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

Report Highlights
  • 11-year Forecast of Adult-onset Still's Disease Epidemiology
  • 7MM Coverage
  • Total Prevalent cases of Adult-onset Still's Disease
  • Diagnosed Cases of Adult-onset Still's Disease
  • Severity-specific Cases of Adult-onset Still's Disease
  • Gender-specific Cases of Adult-onset Still's Disease
KOL Views

The publisher interviews KOLs and include SME's opinion through primary research to fill the data gaps and validate the secondary research. The view helps understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to adult-onset Still's disease?
  • What are the key findings pertaining to the adult-onset Still's disease epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of adult-onset Still's disease across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow by in the 7MM during the forecast period (2017-2030)?
  • What are the disease risks, burdens, and unmet needs of adult-onset Still's disease?
  • What are the currently available treatments of adult-onset Still's disease?
Reasons to Buy

The Adult-onset Still's Disease Epidemiology report will allow the user to:
  • Develop business strategies by understanding the trends shaping and driving the global adult-onset Still's disease market.
  • Quantify patient populations in the global adult-onset Still's disease to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for adult-onset Still's disease therapeutics in each of the markets covered.
  • Understand the magnitude of the adult-onset Still's disease population by its epidemiology.
  • The adult-onset Still's disease Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
1. Key Insights

2. Executive Summary of AOSD

3. Overview and Background
3.1. Introduction
3.2. Etiology
3.3. History and Physical
3.4. Symptoms
3.5. Pathogenesis
3.6. Clinical Manifestation
3.7. AOSD biomarkers
3.8. Diagnosis
3.9. Diagnostic criteria for AOSD

4. Epidemiology and Patient Population
4.1. Key Findings

5. 7MM Epidemiology
5.1. Assumptions and rationale
5.2. Total Prevalent Cases of Adult-onset Still’s Disease (AOSD) in 7MM
5.3. The United States
5.3.1. Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in the United States
5.3.2. Gender-specific cases of Adult-onset Still’s Disease (AOSD) in the United States
5.3.3. Complications Associated with Adult-onset Still’s Disease (AOSD) in the United States
5.4. EU5 Countries
5.4.1. Germany
5.4.2. France
5.4.3. Italy
5.4.4. Spain
5.4.5. United Kingdom
5.5. Japan

6. Treatment

7. Unmet Needs

8. Organizations contributing toward AOSD

9. Case Study
9.1. Adult-onset Still’s disease initially thought to be an odontogenic infection: A case report
9.2. Adult-onset Still’s Disease Complicated by Autoimmune Hepatitis: Successful Treatment with Infliximab
9.3. Complex presentation of adult-onset Still’s disease
9.4. A complete response to steroids in dural inflammatory pseudotumor associated with Still’s disease

10. KOL Views

11. Patient Journey

12. Appendix
12.1. Report Methodology
12.2. References

13. Publisher Capabilities

14. Disclaimer

15. About the Publisher

List of Tables
Table 1: Summary of Adult-onset Still’s Disease Market, Epidemiology, and Key Events (2017-2030)
Table 2: Serum biomarkers in AOSD
Table 3: Total Prevalent Cases of Adult-onset Still’s Disease (AOSD) in the 7MM (2017-2030)
Table 4: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in the United States (2017-2030)
Table 5: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Table 6: Complications Associated with Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Table 7: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Table 8: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Table 9: Complications Associated with Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Table 10: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Table 11: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Table 12: Complications Associated with Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Table 13: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Table 14: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Table 15: Complications Associated with Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Table 16: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Table 17: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Table 18: Complications Associated with Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Table 19: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in the United Kingdom (2017-2030)
Table 20: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Table 21: Complications Associated with Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Table 22: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Table 23: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Table 24: Complications Associated with Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)

List of Figures
Figure 1: Pathogenesis
Figure 2: Total Prevalent Cases of Adult-onset Still’s Disease (AOSD) in the 7MM (2017-2030)
Figure 3: Total Prevalent Cases of AOSD in the United States (2017-2030)
Figure 4: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Figure 5: Complications Associated with Adult-onset Still’s Disease (AOSD) in the US (2017-2030)
Figure 6: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Figure 7: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Figure 8: Complications Associated with Adult-onset Still’s Disease (AOSD) in Germany (2017-2030)
Figure 9: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Figure 10: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Figure 11: Complications Associated with Adult-onset Still’s Disease (AOSD) in France (2017-2030)
Figure 12: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Figure 13: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Figure 14: Complications Associated with Adult-onset Still’s Disease (AOSD) in Italy (2017-2030)
Figure 15: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Figure 16: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Figure 17: Complications Associated with Adult-onset Still’s Disease (AOSD) in Spain (2017-2030)
Figure 18: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Figure 19: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Figure 20: Complications Associated with Adult-onset Still’s Disease (AOSD) in the UK (2017-2030)
Figure 21: Total Prevalent cases of Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Figure 22: Gender-specific cases of Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Figure 23: Complications Associated with Adult-onset Still’s Disease (AOSD) in Japan (2017-2030)
Figure 24: Treatment Algorithm of Adult-onset Still’s Disease
Figure 25: Unmet Needs of Adult-onset Still’s Disease
Note: Product cover images may vary from those shown
Adroll
adroll